<DOC>
	<DOCNO>NCT01271803</DOCNO>
	<brief_summary>This open-label , dose-escalation study vemurafenib combination cobimetinib evaluate safety , tolerability pharmacokinetics participant BRAFV600 mutation-positive metastatic melanoma . Participants previously untreated , BRAFV600E mutation-positive , locally advanced/unresectable metastatic melanoma progress vemurafenib monotherapy immediately prior enrol trial eligible . Participants assign different cohort escalate oral dos vemurafenib cobimetinib . This study consist 2 stage , Stage 1 ( Dose Escalation Stage [ DES ] Cohort Expansion Stage [ CES ] ) anticipate time study treatment disease progression , unacceptable toxicity discontinuation criterion meet .</brief_summary>
	<brief_title>A Study Vemurafenib GDC-0973 ( Cobimetinib ) Participants With BRAFV600E Mutation-Positive Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Participants histologically confirm melanoma ( unresectable Stage IIIc Stage IV metastatic melanoma , define American Joint Committee Cancer [ AJCC ] ) Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) Version ( V ) 1.1 Eastern Cooperative Oncology Group ( ECOG ) Performance Status less equal ( &lt; /= ) 1 Participants must 1. previously untreated locally advanced/unresectable metastatic melanoma 2. previously treat without prior exposure BRAF MEK inhibitor therapy 3. progress vemurafenib participate Phase I ( include clinical pharmacology study ) , II , III clinical study expand access program ( EAP ) immediately prior enrollment study 4. progress vemurafenib administer postmarketing set immediately prior enrollment study . Life expectancy &gt; /=12 week History prior significant toxicity another RAF MEK pathway inhibitor require discontinuation treatment Palliative radiotherapy within 2 week prior first dose study drug treatment Experimental therapy within 4 week prior first dose study drug treatment except vemurafenib Major surgery within 4 week first dose study drug treatment plan major surgery study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>